BenzingaOctober 7, 2026 at 7:38 AM NY20 Days Ago
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
